1. Clinical Overview
A fixed-dose combination (FDC) medication primarily indicated for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that addresses the underlying polyol pathway hyperactivity in diabetes, while pregabalin is an alpha-2-delta ligand that modulates calcium channels to provide symptomatic relief from neuropathic pain. This combination targets both the pathophysiology and the symptoms of diabetic neuropathy.
| Onset | Duration | Bioavailability |
|---|---|---|
| Pregabalin: Pain relief may begin within 1 week, with maximal effect typically seen by 4 weeks. Epalrestat: Slower onset; biochemical effects on nerve sorbitol levels begin quickly, but clinical improvement in neuropathy symptoms (e.g., nerve conduction velocity) may take 3-6 months of continuous therapy. | Pregabalin: Approximately 24 hours with twice-daily dosing. Epalrestat: Its inhibitory effect on aldose reductase is sustained with regular dosing, requiring continuous administration for long-term benefit. | Pregabalin: >90% and is dose-proportional. Epalrestat: Approximately 75-80%. |
2. Mechanism of Action
The combination works via two distinct, complementary mechanisms. Epalrestat inhibits the enzyme aldose reductase, the first and rate-limiting enzyme in the polyol pathway. In hyperglycemia, excess glucose is shunted into this pathway, leading to intracellular accumulation of sorbitol and fructose, depletion of myo-inositol, and oxidative stress, ultimately causing nerve damage. By inhibiting this pathway, epalrestat addresses the metabolic etiology of diabetic neuropathy. Pregabalin binds presynaptically to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding reduces the influx of calcium, which in turn decreases the release of several excitatory neurotransmitters (e.g., glutamate, noradrenaline, substance P). The net effect is a reduction in the hyperexcitability of neurons that underlies neuropathic pain.
3. Indications & Uses
- Management of painful Diabetic Peripheral Neuropathy (DPN)
- Symptomatic treatment of neuropathic pain associated with diabetic neuropathy
4. Dosage & Administration
Adult Dosage: One tablet (Epalrestat 150mg + Pregabalin 150mg) orally, twice daily. May be initiated at a lower dose (e.g., Pregabalin 75mg) and titrated based on response and tolerability, but this FDC is a maintenance strength.
Administration: Can be taken with or without food. Swallow whole with a glass of water. Do not crush or chew. The tablet should be taken at regular intervals, approximately every 12 hours. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.
5. Side Effects
Common side effects may include:
- Dizziness
- Somnolence (drowsiness)
- Peripheral edema
- Weight gain
- Headache
- Dry mouth
- Blurred vision
- Fatigue
- Nausea
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Potentiated sedation, dizziness, respiratory depression, and increased risk of accidents. | Major |
| Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Enalapril) | Increased risk and severity of peripheral edema and angioedema. | Major |
| Thiazolidinediones (Pioglitazone, Rosiglitazone) | Additive risk of peripheral edema and weight gain. | Moderate |
| Oxycodone, Lorazepam | Pregabalin may increase their peak plasma concentrations, enhancing CNS effects. | Moderate |
| Strong Inducers of UGT (e.g., Rifampicin) | May decrease plasma concentrations of Epalrestat by increasing its glucuronidation, reducing efficacy. | Moderate |
7. Patient Counselling
- DO take the medicine exactly as prescribed, at the same times each day.
- DO inform all your doctors and dentists that you are taking this medicine.
- DO monitor your weight regularly and report sudden increases or swelling in legs/feet.
- DO NOT stop taking this medicine suddenly. Always consult your doctor for a tapering schedule.
- DO NOT consume alcohol while on this medication.
- DO NOT drive or operate heavy machinery until you are sure the medicine does not make you dizzy or drowsy.
- DO NOT take any other medication (including OTC, herbal) without consulting your doctor.
8. Toxicology & Storage
Overdose: Primarily reflects pregabalin toxicity: Severe drowsiness, sedation, blurred vision, diplopia, slurred speech, confusion, agitation, restlessness, depression, seizures, coma. Bradycardia and heart block have been reported. Epalrestat overdose may potentiate GI upset and lethargy.
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children and pets. Do not use after the expiry date printed on the pack.